Next generation T cell therapies for solid cancers.


Tumor-infiltrating lymphocytes show consistent clinical benefit in metastatic melanoma, but they are a poorly defined product with variable antitumor activity. In this issue, Palmer et al.1 create for clinical testing a cell product consisting of highly functional tumor-reactive T cells by knocking out CISH, an inhibitor of T cell activation.

More about this publication

Med (New York, N.Y.)
  • Volume 3
  • Issue nr. 10
  • Pages 645-647
  • Publication date 14-10-2022

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.